

Medications used to treat the motor symptoms of Parkinson's disease as of October 2020

Mechanism of action	Generic name	Trade name®	Potential side effects*	
DOPA Decarboxylase inhibitor/DA precursor	Carbidopa/Levodopa	Sinemet	Nausea, dizziness, orthostatic hypotension, anxiety, dyskinesia, confusion, hallucinations,	
	Carbidopa/Levodopa ER (extended release)			
	Carbidopa/Levodopa (orally disintegrating)	Parcopa	somnolence, peripheral neuropathy (acute and subacute forms more	
	Carbidopa/Levodopa (extended release capsules)	Rytary	common with Duopa)	
	Carbidopa/Levodopa (enteral suspension)	Duopa		
	Levodopa inhalation powder	Inbrija		
COMT inhibitor, inhibits breakdown of levodopa	Entacapone	Comtan	Same as carbidopa/ levodopa. In addition:	
	Tolcapone	Tasmar	diarrhea, discoloration of body fluids	
	Opicapone	Ongentys	Tasmar can cause liver failure and requires monitoring of liver function	
DOPA decarboxylase inhibitor/DA precursor/ COMT Inhibitor	Carbidopa/Levodopa/ Entacapone	Stalevo	Same as carbidopa/ levodopa and COMT inhibitor	
DA agonist	Pramipexole	Mirapex	Nausea, dizziness,	
	Pramipexole (extended release)	Mirapex ER	orthostatic hypotension, swelling of ankles, dyskinesia, hallucinations, confusion, somnolence, sleep attacks, impulse control disorders Neupro can lead to a skin reaction at the patch site	
	Ropinirole	Requip		
	Ropinirole (extended release)	Requip XL		
	Apomorphine (injection)	Apokyn		
	Apomorphine (sublingual film)	Kynmobi		
	Rotigotine (transdermal patch)	Neupro		



Mechanism of action	Generic name	Trade name®	Potential side effects*	
MAO-B inhibitor, inhibits breakdown of dopamine	Selegiline		Selegiline can cause insomnia Dizziness, nausea, gastrointestinal upset, dyskinesia, hallucinations,	
	Selegiline (orally disintegrating)	Zelapar		
	Rasagiline	Azilect		
	Safinamide	Xadago	confusion, headache	
			Note possible drug interactions between MAO-B inhibitors and other medications	
			Safinamide exerts its effects through other mechanisms of action as well	
Adenosine 2A inhibitor	Istradefylline	Nourianz	Dyskinesias, dizziness, constipation, nausea, hallucinations and insomnia	
Mixed mechanisms, including NMDA antagonism	Amantadine		Hallucinations, leg swelling, dizziness, mottled skin (livedo reticularis), confusion, dry mouth and eyes, constipation, dizziness, orthostatic hypotension, somnolence	
	Amantadine (extended release)	Gocovri		
	Amantadine (extended release)	Osmolex ER		
			Dose needs to be adjusted for kidney dysfunction	
Anticholinergic	Trihexyphenidyl		Dry mouth and eyes, constipation, urinary retention, memory impairment, confusion, depression, hallucinations	
	Benztropine	Cogentin		



Medications used to treat the non-motor symptoms of Parkinson's disease as of October 2020**


Symptom treated	Mechanism of action	Generic name	Trade name®	Potential side effects*
Parkinson's disease psychosis	Inverse serotonin agonist	Pimavanserin	Nuplazid	Swelling of legs or arms, nausea, confusion, constipation QT interval prolongation (abnormal heart rhythm), increased risk of death in elderly patients with dementia-related psychosis
Neurogenic orthostatic hypotension	Norepinephrine precursor	Droxidopa	Northera	Headache, dizziness, nausea, high blood pressure (especially when lying down)
Parkinson's disease dementia	Acetylcholinesterase inhibitor	Rivastigmine	Exelon	Stomach upset, nausea, loss of appetite

COMT = cathechol-o-methyltransferase DA = dopamine DOPA = dopamine MAO-B = monoamine oxidase B NMDA = n-methyl-d-aspartate

* Additional side effects may occur. Please discuss with your health care provider.

** The medications listed carry a specific indication for use in Parkinson's disease. Many other medications are used off-label for treatment of non-motor symptoms of Parkinson's disease.





This material is intended to provide you with information. It should not be used for treatment purposes, but rather as a source for discussion with your own physician. Work with your physician to determine which medications are best for you, and know the risks and benefits of each.

AMERICAN PARKINSON DISEASE ASSOCIATION

(800) 223-2732 • apdaparkinson.org

© Revised and Updated by Rebecca Gilbert, MD, PhD, APDA Vice President, Chief Scientific Officer – October 2020